Endothelial cell-derived plasminogen activator inhibitor-1 potentiates thrombosis in antiphospholipid syndrome
Document Type
Article
Publication Date
2026
Department/School
Chemistry
Publication Title
Journal of Autoimmunity
Abstract
Background: Plasminogen activator inhibitor-1 (PAI-1) plays a key role in modulating fibrinolysis. However, its role in the thrombotic autoimmune disease known as antiphospholipid syndrome (APS) remains understudied. Methods: We characterized PAI-1 expression by APS endothelial cells through single-cell RNA sequencing (scRNA-seq) of skin biopsies from APS patients with active livedo racemosa and age-matched controls. Total and active PAI-1 were quantified in plasma samples from 167 patients with APS, 37 antiphospholipid antibody- positive carriers without clinical APS, 18 patients with a history of non-APS thrombosis, and 48 healthy controls. In vitro, human microvascular endothelial cells (MVECs) were cultured with IgG isolated from patients with APS, and PAI-1 mRNA and protein levels were evaluated by quantitative PCR and ELISA, respectively. Finally, a mouse model of APS IgG-accelerated venous thrombosis induced by electrolytic injury of the inferior vena cava was used to determine the impact of the PAI-1 inhibitor MDI-2268 on thrombosis. Results: scRNA-seq revealed significantly increased SERPINE1 (PAI-1) expression in endothelial cells from patients with APS. Compared with healthy controls, active PAI-1 was detected at significantly higher levels in the plasma of patients with thrombotic APS, where it showed a positive correlation with absolute neutrophil count, erythrocyte sedimentation rate, and C-reactive protein. APS patients with increased antibody burden, as determined by a higher adjusted global APS score (aGAPSS ≥7 versus <7), had more active PAI-1 in their plasma. In vitro, APS IgG stimulation of MVECs increased PAI-1 transcription and secretion, which were dependent on NF-κB signaling. In mice, the administration of APS IgG significantly increased thrombus weights, which was mitigated by MDI-2268. Conclusion: Together, these findings suggest that endothelial cells are a likely source of increased active PAI-1 in APS. Furthermore, blocking PAI-1 activity effectively reduced APS IgG-accelerated thrombosis in mice, suggesting that PAI-1 inhibition has therapeutic potential in APS.
Link to Published Version
Recommended Citation
Gan, Y., Liang, W., Liu, C., Yalavarthi, S., Warnock, M., Sabb, K., Sarosh, C., Schaefer, J. K., Tambralli, A., Madison, J. A., Emal, C. D., Tsou, P.-S., Shi, H., Zuo, Y., Lawrence, D. A., & Knight, J. S. (2026). Endothelial cell-derived plasminogen activator inhibitor-1 potentiates thrombosis in antiphospholipid syndrome. Journal of Autoimmunity, 161, 103563. https://doi.org/10.1016/j.jaut.2026.103563
Comments
See the article text for a complete list of authors and their affiliations.
C. D. Emal is a faculty member in EMU's Department of Chemistry.